Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

You can access the MAYZENT resources for patients below, which you can use with your SPMS patients. The materials are designed to help them manage their symptoms, better understand their disease and improve doctor–patient communication.

If you would like to receive printed copies of any of these materials, please contact your local MAYZENT key account manager.

 

Thumbnail of Introduction to Mayzent booklet.
 

INTRODUCTION TO MAYZENT

Patient resource to explain how MAYZENT works and how MAYZENT can help SPMS patients with active disease.

Preview

Thumbnail of Before you start Mayzent booklet.
 

BEFORE YOU START MAYZENT

Patient resource to provide details around pre-initiation requirement with MAYZENT for SPMS patients with active disease.

Preview

Thumbnail of Starting treatment with Mayzent booklet.
 

STARTING TREATMENT WITH MAYZENT

Patient resource to provide details around the treatment initiation process and requirements with MAYZENT for SPMS patients with active disease.

Preview

 

Thumbnail of Continuing treatment with Mayzent booklet.
 

CONTINUING TREATMENT WITH MAYZENT

Patient resource to provide details around ongoing monitoring and adherence requirements while on MAYZENT.

Preview

Thumbnail of Mayzent discussion guides.
 

MAYZENT DISCUSSION GUIDES TO SUPPORT HCP DISCUSSIONS WITH PATIENTS

Guides to support discussions between HCPs and patients prescribed MAYZENT, introducing the treatment and providing details on pre-initiation, starting and continuing treatment. Included is one discussion guide for HCP use only, providing greater detail on each topic, and one discussion guide for use with patients.

Preview

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.

Reference:

  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | June 2021 | 103440
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]